Business Wire

Bentley Systems Announces Acquisition of Mobility Simulation Leader INRO

15.4.2021 01:04:00 EEST | Business Wire | Press release

Share

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the acquisition of INRO Software, a global leader in multimodal transportation planning, traffic simulation, and mobility visualization software. The acquisition expands Bentley’s capabilities in the important growth area of mobility digital twins, just as countries including the U.S. are poised to make a generational investment in infrastructure, and as transportation systems must evolve faster to accommodate both urbanization and carbon reduction goals, and the transition to electric and autonomous vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005928/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Image produced with Emme (www.inrosoftware.com/emme) using data from Metro (https://www.oregonmetro.gov/) (Image courtesy of INRO)

INRO, based in Montreal, Quebec, Canada, has for more than 40 years contributed to the advancement of mobility simulation and modeling for metropolitan, regional, and national transport and transit operators and planning agencies. Users of its multimodal simulation offerings include some of the world’s busiest transit systems and metros, such as Transport for London, Transport for New South Wales, the Washington State Department of Transportation, the Swedish Transport Administration Trafikverket, and the public transport system of São Paulo SPTrans.

INRO’s products include Emme, a multimodal transportation planning system for urban, regional, and national transportation forecasting; Dynameq, a vehicle-based traffic simulation platform for city-wide traffic planning; and CityPhi, a mobility visualization solution providing data visualization and visual analytics of large-scale mobility and geospatial datasets.

Combining the capabilities of INRO’s advanced traffic and vehicle simulation with Bentley’s passenger and pedestrian simulation and civil design software, including CUBE, Streetlytics, LEGION, and OpenRoads, places Bentley in a very strong position to deliver comprehensive mobility digital twins of multimodal transportation systems at urban, metropolitan, regional, and national scale.

Advancing Mobility Digital Twins

Urban planners are seeking to understand the ongoing impacts—on transportation system performance, reliability, and accessibility—of the new opportunities and challenges of private and shared mobility, the propensity for cycling or walking, connected autonomous vehicles, and potential congestion charging. With respect to their traditionally circumscribed use of transportation modeling tools in isolation and only on occasion, multiple advantages are now attainable through mobility digital twins, which can be continuously updated with as-operated engineering conditions and with observed traffic data. Mobility digital twins bring these functions together so that infrastructure planning and simulations can be continuously valuable throughout engineering, construction, and operations.

The pandemic experience reinforces the resilience value of sustaining “evergreen” planning and engineering modeling and simulation to maintain fitness for purpose during unanticipated eventualities. With the priority now on “building back better,” it is increasingly recognized that the most economical way to augment infrastructure capacity, while accomplishing the needed energy transitions toward climate sustainability, is to optimize the utilization, configuration, and life extension of existing mobility assets, while adding integrated and appealing public transit options.

This requirement now sets the stage for mobility digital twins that need to be multimodal, need detailed dynamic traffic assignment and agent-based methods for veracity, and need to scale up to systemwide and regionwide—uniquely hallmarks of INRO. As the leader in infrastructure digital twins, Bentley’s iTwin platform can now bring together—with the best-validated aggregate and individual vehicle and pedestrian simulation—3D/4D continuous surveying and reality modeling, civil engineering and project delivery, and asset and network performance. Ultimately, the opportunity for digital cities is to save their constituents time in their day, while at the same time improving congestion and climate resilience, and safety.

“We are very pleased to welcome INRO to Bentley Systems,” said Robert Mankowski, senior vice president, digital cities, Bentley Systems. “Professor Michael Florian and his team led the research of advanced multimodal network modeling methods which helped establish state-of-the-art mobility simulation, and in this next generation his son Dan is leading its software future in our mobility digital twin advancement. With the addition of INRO and its world-class team, Bentley Systems can even better accelerate cities and regions in going digital to ‘build back better’!”

Dr. Michael Florian, founder of INRO, said, “Bentley is a recognized leader in transportation across the infrastructure lifecycle from planning and design to heavy civil construction and road network management. My colleagues and I are very excited to join Bentley and to help realize the vision shared by thousands of cities and urban regions throughout the world to improve their sustainability and quality of life.”

Image 1: Emme

Caption: Image produced with Emme (www.inrosoftware.com/emme) using data from Metro (https://www.oregonmetro.gov/)

Image 2: Dynameq

Caption: Image produced with Dynameq (www.inrosoftware.com/dynameq) using data from SFCTA (https://www.sfcta.org/)

Image 3: CityPhi

Caption: Image produced with CityPhi (www.inrosoftware.com/cityphi) using data from http://www.andresmh.com/nyctaxitrips/

Image 4: INRO Products

Caption: INRO is a global leader in multimodal transportation planning, traffic simulation, and mobility visualization software

Video: Seattle synthetic travel demand model

Caption: Illustration of ~20 million activities completed over the course of a day by 3.6 million people from a synthesized travel demand model of the Seattle metropolitan region. Activities are shown as time-animated vertical extrusions of population movements colored by purpose. The heads-up display summarizes the visible population by current activity. Video prepared by INRO using CityPhi (www.inrosoftware.com/cityphi). More information on source data, provided by PSRC, is available at https://www.psrc.org/activity-based-travel-model-soundcast.

About Bentley Systems

Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annualized revenues of more than $800 million in 172 countries. www.bentley.com

© 2021 Bentley, the Bentley logo, AssetWise, CUBE, INRO, Emme, Dynameq, CityPhi, iTwin, LEGION, MicroStation, OpenRoads, ProjectWise, and Streetlytics are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye